Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GZR102 vs GZR4 and GZR18 in Overweight Subjects
NCT06974487Phase 1Not yet recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- May 2025
- Primary completion
- Sep 2025
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GZR102 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to Time t at Day 36. Planned start May 2025; status: not yet recruiting.
02
Drugs
GZR102
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06974487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06974487.